We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBaillie Geu Regulatory News (BGEU)

Share Price Information for Baillie Geu (BGEU)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 94.90
Bid: 94.60
Ask: 95.40
Change: -0.50 (-0.52%)
Spread: 0.80 (0.846%)
Open: 94.40
High: 94.90
Low: 94.40
Prev. Close: 95.40
BGEU Live PriceLast checked at -
Baillie Gifford European Growth is an Investment Trust

To achieve attractive capital growth over the long term from a diversified portfolio of European securities.

Find out More

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Annual Financial Report

10 Dec 2021 14:26

RNS Number : 3266V
Baillie Gifford European Growth Tst
10 December 2021
 

Baillie Gifford European Growth Fund plc (BGEU)

 

Legal Entity Identifier: 213800QNN9EHZ4SC1R12

Regulated Information Classification: Annual Financial and Audit Reports

 

Annual Report and Financial Statements

 

Further to the preliminary statement of audited annual results announced to the Stock Exchange on 24 November 2021, Baillie Gifford European Growth Trust PLC ("the Company") announces that the Company's Annual Report and Financial Statements for the year ended 30 September 2021, including the Notice of Annual General Meeting, has been posted to shareholders and submitted electronically to the National Storage Mechanism where it will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism 

It is also available on the Company's page of the Baillie Gifford website at: www.bgeuropeangrowth.com (as is the preliminary statement of audited annual results announced by the Company on 24 November 2021).

 

Covid-19 coronavirus - arrangements for the Annual General Meeting (AGM)

Subject to Government measures restricting public gatherings, and related public health guidance associated with the Covid-19 pandemic, the Annual General Meeting of the Company will be held at the Institute of Directors, 116 Pall Mall, London SW1Y 5ED on Thursday, 3 February 2022, at 11am. Given the ongoing uncertainty, the Board will continue to monitor developments and may be forced to prohibit shareholders from attending in person. The Board therefore encourages all shareholders to exercise their votes at the Annual General Meeting by completing and submitting a form of proxy; and to monitor the Company's website at www.bgeuropeangrowth.com where any updates will be posted. Should shareholders have questions for the Board or the Managers or any queries as to how to vote, they are welcome as always to submit them by email to trustenquiries@bailliegifford.com or call 0800 917 2112. Baillie Gifford may record your call.

 

 

Statement of Directors' Responsibilities in respect of the Annual Report and the Financial Statements

Each of the Directors, whose names and functions are listed within the Directors and Managers section of the Annual Report and Financial Statements, confirm that, to the best of their knowledge:

¾ the Financial Statements, prepared in accordance with the applicable set of accounting standards, give a true and fair view of the assets, liabilities, financial position and net return of the Company;

¾ the Strategic Report includes a fair review of the development and performance of the business and the position of the Company, together with a description of the principal risks and uncertainties that it faces (as also set out below); and

¾ the Annual Report and Financial Statements, taken as a whole, is fair, balanced and understandable and provides the information necessary for shareholders to assess the Company's position and performance, business model and strategy.

 

 

Principal Risks relating to the Company

 

As explained on pages 25 and 26 of the Annual Report and Financial Statements there is an ongoing process for identifying, evaluating and managing the risks faced by the Company. The Directors have undertaken a robust assessment of the principal and emerging risks facing the Company, including those that would threaten the business model, future performance, solvency or liquidity. A description of these risks and how they are being managed or mitigated is set out below:

 

Financial Risk - The Company's assets at present consist mainly of listed securities. Its principal and emerging risks are therefore market related and include market risk (comprising currency risk, interest rate risk and other price risk), liquidity risk and credit risk. Explanations of those risks and how they are managed or mitigated are contained in note 19 to the Financial Statements on pages 50 to 54 of the Annual Report and Financial Statements. The Board has, in particular, considered the impact of market volatility during the Covid-19 pandemic. In monitoring this risk, the Board considers at each meeting various portfolio metrics including individual stock performance, the composition and diversification of the portfolio by sector, purchases and sales of investments and the top and bottom contributors to performance. The Manager provides rationale for stock selection decisions.

 

Investment Strategy Risk - pursuing an investment strategy to fulfil the Company's objective which the market perceives to be unattractive or inappropriate, or the ineffective implementation of an attractive or appropriate strategy, may lead to reduced returns for shareholders and, as a result, a decreased demand for the Company's shares. This may lead to the Company's shares trading at a widening discount to their net asset value. To mitigate this risk, the Board regularly reviews and monitors: the Company's objective and investment policy and strategy; the investment portfolio and its performance; the level of discount/premium to net asset value at which the shares trade; and movements in the share register.

 

Discount Risk - the discount/premium at which the Company's shares trade relative to its net asset value can change. The risk of a widening discount is that it may undermine investor confidence in the Company. To manage this, the Board monitors the level of discount/premium at which the shares trade and the Company has authority to buy back its existing shares when deemed by the Board to be in the best interests of the Company and its shareholders in aggregate.

 

Regulatory Risk - failure to comply with applicable legal and regulatory requirements such as the tax rules for investment companies, the FCA Listing Rules and the Companies Act could lead to suspension of the Company's Stock Exchange listing, financial penalties, a qualified audit report or the Company being subject to tax on capital gains. To mitigate this, Baillie Gifford's Business Risk, Internal Audit and Compliance Departments provide regular reports to the Company's Audit Committee on Baillie Gifford's monitoring programmes. Major regulatory change could impose disproportionate compliance burdens on the Company. In such circumstances representation is made to ensure that the special circumstances of investment trusts are recognised. Shareholder documents and announcements, including the Company's published Interim and Annual Report and Financial Statements, are subject to stringent review processes, and procedures are in place to ensure adherence to the Transparency Directive and the Market Abuse Directive with reference to inside information.

 

Custody and Depositary Risk - safe custody of the Company's assets may be compromised through control failures by the Depositary, including cyber security incidents. To mitigate this risk, the Audit Committee receives bi-annual reports from the Depositary confirming safe custody of the Company's assets held by the Custodian. Cash and portfolio holdings are independently reconciled to the Custodian's records by the Managers. The Custodian's audited internal controls reports are reviewed by Baillie Gifford's Business Risk Department and a summary of the key points is reported to the Audit Committee and any concerns investigated. In addition, the existence of assets is subject to annual external audit.

 

 

Operational Risk - failure of Baillie Gifford's systems or those of other third party service providers could lead to an inability to provide accurate reporting and monitoring or a misappropriation of assets. To mitigate this risk, Baillie Gifford has a comprehensive business continuity plan which facilitates continued operation of the business in the event of a service disruption (including any disruption resulting from the Covid-19 pandemic) or major disaster. Baillie Gifford has continued to operate on a business-as-usual basis throughout the Covid-19 pandemic. Following the relaxation of Covid-19 restrictions by the Scottish and UK governments, we have continued to see a gradual increase in office attendance. A hybrid model is now operating, with staff determining the most appropriate split between working from home and working in the office. The Board reviews Baillie Gifford's Report on Internal Controls and the reports by other key third party providers are reviewed by Baillie Gifford on behalf of the Board. In the year under review, the other key third party service providers have not experienced significant operational difficulties affecting their respective services to the Company.

 

Leverage Risk - the Company may borrow money for investment purposes (sometimes known as 'gearing' or 'leverage'). If the investments fall in value, any invested borrowings will magnify the impact of this loss. If borrowing facilities are not renewed, the Company may have to sell investments to repay borrowings. To mitigate this, all borrowings require the prior approval of the Board and leverage levels are discussed by the Board and Managers at every meeting. Covenant levels are monitored regularly. The majority of the Company's investments are in quoted securities that are readily realisable. Further information on leverage can be found on page 63 of the Annual Report and Financial Statements. and in the Glossary of Terms and Alternative Performance Measures on pages 64 and 65 of the Annual Report and Financial Statements.

 

Political Risk - political developments are closely monitored and considered by the Board. Following the departure of the UK from the European Union, the Board continues to assess the potential consequences for the Company's future activities including those that may arise from further constitutional change.

 

Emerging Risks - as explained on pages 25 to 26 of the Annual Report and Financial Statements, the Board has regular discussions on principal risks and uncertainties, including any risks which are not an immediate threat but could arise in the longer term. The Board considers that the key emerging risks arise from two areas. Firstly, from the global reach of the investment portfolio and its exposure to external and emerging threats such as cyber risk and coronavirus. This is mitigated by the Investment Managers' close links to the investee companies and their ability to ask questions on contingency plans. The Investment Managers believe the impact of such events may be to slow growth rather than to invalidate the investment rationale. Secondly, as investors place increased emphasis on Environmental, Social and Governance issues (ESG), any failure by the Investment Managers to identify potential future problems on ESG matters in an investee company could lead to the Company's shares being less attractive to investors as well as potential valuation issues in the underlying investee company.

This is mitigated by the Investment Managers' ESG application, which is integrated into the investment process, as well as the extensive up-front and ongoing due diligence which the Investment Managers undertake on each investee company. This includes the risks inherent in climate change (see page 27 of the Annual Report and Financial Statements).

 

Baillie Gifford & Co Limited

Company Secretaries

10 December 2021

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSFFLFLSEFSEEE
Date   Source Headline
19th Apr 20243:41 pmRNSDirector/PDMR Shareholding
19th Apr 20241:24 pmRNSNet Asset Value(s)
18th Apr 202411:26 amRNSNet Asset Value(s)
17th Apr 20244:59 pmRNSTransaction in Own Shares
17th Apr 202412:10 pmRNSNet Asset Value(s)
16th Apr 20244:05 pmRNSNet Asset Value(s)
15th Apr 202412:07 pmRNSNet Asset Value(s)
12th Apr 20244:57 pmRNSTransaction in Own Shares
12th Apr 202411:37 amRNSNet Asset Value(s)
11th Apr 20245:13 pmRNSTransaction in Own Shares
11th Apr 202411:12 amRNSNet Asset Value(s)
10th Apr 202412:06 pmRNSNet Asset Value(s)
9th Apr 20245:12 pmRNSTransaction in Own Shares
9th Apr 202411:23 amRNSNet Asset Value(s)
8th Apr 202411:06 amRNSNet Asset Value(s)
5th Apr 202411:47 amRNSNet Asset Value(s)
4th Apr 202411:21 amRNSNet Asset Value(s)
3rd Apr 20245:25 pmRNSTransaction in Own Shares
3rd Apr 202411:17 amRNSNet Asset Value(s)
2nd Apr 20245:14 pmRNSClosed Period Confirmation
2nd Apr 20244:31 pmRNSNet Asset Value(s)
2nd Apr 20243:58 pmRNSNet Asset Value(s)
2nd Apr 20242:54 pmRNSTotal Voting Rights
2nd Apr 20241:41 pmRNSNet Asset Value(s)
28th Mar 20244:53 pmRNSTransaction in Own Shares
28th Mar 202411:45 amRNSNet Asset Value(s)
27th Mar 202411:53 amRNSNet Asset Value(s)
26th Mar 20244:56 pmRNSTransaction in Own Shares
26th Mar 202411:38 amRNSNet Asset Value(s)
25th Mar 202412:20 pmRNSNet Asset Value(s)
22nd Mar 202412:06 pmRNSNet Asset Value(s)
21st Mar 202411:51 amRNSNet Asset Value(s)
20th Mar 20245:46 pmRNSTransaction in Own Shares
20th Mar 202412:12 pmRNSNet Asset Value(s)
19th Mar 20242:24 pmRNSHolding(s) in Company
19th Mar 202412:28 pmRNSNet Asset Value(s)
18th Mar 20243:50 pmRNSNet Asset Value(s)
15th Mar 20245:18 pmRNSTransaction in Own Shares
15th Mar 20242:09 pmRNSNet Asset Value(s)
14th Mar 20244:54 pmRNSTransaction in Own Shares
14th Mar 202411:17 amRNSNet Asset Value(s)
13th Mar 20245:25 pmRNSTransaction in Own Shares
13th Mar 20243:19 pmRNSHolding(s) in Company
13th Mar 202411:28 amRNSNet Asset Value(s)
12th Mar 202411:27 amRNSNet Asset Value(s)
11th Mar 202411:00 amRNSNet Asset Value(s)
8th Mar 202412:03 pmRNSNet Asset Value(s)
7th Mar 202412:18 pmRNSNet Asset Value(s)
6th Mar 20245:22 pmRNSTransaction in Own Shares
6th Mar 202412:42 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.